QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.053819v1 307/1/349    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kumar, R. K. Articles by Foster, P. S. Search for Related Content PubMed PubMed Citation Articles by Kumar, R. K. Articles by Foster, P. S.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma

Department of Pathology (R.K.K., C.H.) and Prince of Wales Hospital Clinical School (P.S.T.), University of New South Wales, Sydney, Australia; Department of Pharmacology, ALTANA Pharma AG, Konstanz, Germany (L.W., R.B.); and Division of Molecular Biosciences, John Curtin School of Medical Research, Australian National University, Canberra, Australia (M.Y., D.C.W., P.S.F.)

Phosphodiesterase (PDE) inhibitors have potential as alternatives or adjuncts to glucocorticoid therapy in asthma. We compared roflumilast (a selective PDE4 inhibitor) with pentoxifylline (a nonselective inhibitor) and dexamethasone in ameliorating the lesions of chronic asthma in a mouse model. BALB/c mice sensitized to ovalbumin were chronically challenged with aerosolized antigen for 6 weeks. During weeks 5 and 6, groups of animals were treated with roflumilast or dexamethasone by daily gavage or with pentoxifylline by daily intraperitoneal injection. Airway hyper-reactivity (AHR) was evaluated by whole-body plethysmography and airway lesions by histomorphometry and immunohistochemistry. Compared with vehicle alone, treatment with roflumilast or dexamethasone significantly reduced accumulation of eosinophils and chronic inflammatory cells, subepithelial collagenization, and thickening of the airway epithelium. Dexamethasone also reduced goblet cell hyperplasia/metaplasia, subepithelial accumulation of transforming growth factor-1, and epithelial cytoplasmic immunoreactivity for nuclear factor-B. Treatment with pentoxifylline inhibited only eosinophil recruitment and epithelial thickening. Roflumilast and dexamethasone slightly decreased AHR, whereas this was significantly reduced by pentoxifylline. Thus, in this model of chronic asthma, both roflumilast and dexamethasone were potent inhibitors of airway inflammation and remodeling. Roflumilast did not diminish accumulation of transforming growth factor-1, suggesting that it might affect remodeling by mechanisms distinct from glucocorticoids.

Address correspondence to: R. K. Kumar, Department of Pathology, University of New South Wales, Sydney, Australia 2052. E-mail: r.kumar{at}unsw.edu.au

This article has been cited by other articles:

				E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Eur. Respir. J., September 1, 2007; 30(3): 574 - 588. [Abstract] [Full Text] [PDF]

				H. W. J. Young, O. W. Williams, D. Chandra, L. K. Bellinghausen, G. Perez, A. Suarez, M. J. Tuvim, M. G. Roy, S. N. Alexander, S. J. Moghaddam, et al. Central Role of Muc5ac Expression in Mucous Metaplasia and Its Regulation by Conserved 5' Elements Am. J. Respir. Cell Mol. Biol., September 1, 2007; 37(3): 273 - 290. [Abstract] [Full Text] [PDF]

				T. D. Bethke, G. M. Bohmer, R. Hermann, B. Hauns, R. Fux, K. Morike, M. David, D. Knoerzer, W. Wurst, and C. H. Gleiter Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor J. Clin. Pharmacol., January 1, 2007; 47(1): 26 - 36. [Abstract] [Full Text] [PDF]

				B. Hauns, R. Hermann, A. Hunnemeyer, R. Herzog, D. Hauschke, K. Zech, and T. D. Bethke Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J. Clin. Pharmacol., October 1, 2006; 46(10): 1146 - 1153. [Abstract] [Full Text] [PDF]

				C. Bergeron and L.-P. Boulet Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest, April 1, 2006; 129(4): 1068 - 1087. [Abstract] [Full Text] [PDF]

				W. R. Henderson Jr., G. K. S. Chiang, Y.-t. Tien, and E. Y. Chi Reversal of Allergen-induced Airway Remodeling by CysLT1 Receptor Blockade Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 718 - 728. [Abstract] [Full Text] [PDF]

				E. Lopez, V. del Pozo, T. Miguel, B. Sastre, C. Seoane, E. Civantos, E. Llanes, M. L. Baeza, P. Palomino, B. Cardaba, et al. Inhibition of Chronic Airway Inflammation and Remodeling by Galectin-3 Gene Therapy in a Murine Model J. Immunol., February 1, 2006; 176(3): 1943 - 1950. [Abstract] [Full Text] [PDF]

				H.-F. Tang, Y.-H. Song, J.-C. Chen, J.-Q. Chen, and P. Wang Upregulation of Phosphodiesterase-4 in the Lung of Allergic Rats Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 823 - 828. [Abstract] [Full Text] [PDF]

				R. K. Kumar, C. Herbert, D. C. Webb, L. Li, and P. S. Foster Effects of Anticytokine Therapy in a Mouse Model of Chronic Asthma Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1043 - 1048. [Abstract] [Full Text] [PDF]